Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo

Psychopharmacology Bulletin

Volumn 33, Issue 4, 1997, Pages 659-665

  Preskorn, Sheldon H ^a   Alderman, Jeff ^b   Greenblatt, David J ^c   Horst, W Dale ^a  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b PFIZER INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alprazolam; Carbamazepine; Cytochrome P450 3A; Sertraline; Terfenadine

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; PLACEBO; SERTRALINE; TERFENADINE;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

1-NAPHTHYLAMINE; ADOLESCENT; ADULT; ALPRAZOLAM; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CARBAMAZEPINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUBSTRATE SPECIFICITY; TERFENADINE;

EID: 0031405692     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Ereshefsky, L. Drug-drug interactions involving antidepressants: Focus on venlafaxine. J. Clin. Psychopharmacol. 16(3):37-50, 1996.
2. Fleishaker, JC, and Hulst, LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol. 46:35-39, 1994.
3. Greenblatt, DJ; Javaid, JI; Locniskar, A; Harmatz, JS; and Shader, RI. Gas chromatographic analysis of alprazolam in plasma: Replicability, stability, and specificity. J. Chromatogr. 534:202-207, 1990.
4. Harvey, A, and Preskorn, S. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 16:273-285 (Part I) and 345-355 (Part II), 1996.
5. Ketter, T; Flockhart, D; Post, R; Denicoff, K; Pazzaglia, P; Marangell, L; George, M; and Callahan, A. The emerging role of cytochrome P450 3A in psychopharmacology. J. Clin. Psychopharmacol. 15(6):387-398, 1995.
6. Preskorn, S. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. 1st ed. Caddo, OK: Professional Communications, Inc., 1996. pp. 1-255.
7. Rapeport, WG; Williams, SA; Muirhead, DC; Dewland, PM; Tanner, T; and Wesnes, K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry 57:(Suppl. 1):20-23, 1996.
8. Shad, MU; Carmichael, CA; Preskorn, S; and Horst, WD. "Prevalence of polypharmacy in different clinical settings and its relation to drug-drug interactions." Presented at the American Psychiatric Association, San Diego, CA, 1997.
9. von Moltke, LL; Greenblatt, DJ; Court, MH; Duan, SX; Harmatz, JS; and Shader, RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15:125-131, 1995.
10. von Moltke, LL; Greenblatt, DJ; Duan, SX; Harmatz, JS; Wright, CE; and Shader, RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J. Clin. Psychopharmacol. 16:104-112, 1996.
11. Wesnes, K; Simpson, PM; and Kidd, AG. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg. Hum. Psychopharmacol. 3:27-43, 1988.